Vitronectin

A blood plasma glycoprotein that mediates cell adhesion and interacts with proteins of the complement, coagulation, and fibrinolytic cascade. (From Segen, Dictionary of Modern Medicine, 1992)

Networked: 565 relevant articles (6 outcomes, 68 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lawrence, Daniel A: 9 articles (06/2014 - 08/2003)
2.	Reuning, Ute: 8 articles (11/2014 - 07/2003)
3.	Upton, Zee: 6 articles (01/2014 - 06/2003)
4.	Carreiras, Franck: 6 articles (10/2013 - 06/2005)
5.	Leavesley, David I: 5 articles (01/2014 - 03/2008)
6.	Leroy-Dudal, Johanne: 5 articles (10/2013 - 06/2005)
7.	Schmitt, Manfred: 5 articles (08/2009 - 07/2003)
8.	Lityńska, Anna: 4 articles (04/2015 - 12/2008)
9.	Declerck, Paul J: 4 articles (06/2013 - 06/2003)
10.	Gils, Ann: 4 articles (06/2013 - 06/2003)

Related Diseases

1.	Fibrosis (Cirrhosis) 04/01/2004 - "In this study, we compared the levels of alphavbeta5 and matrix-bound vitronectin between normal and scleroderma fibroblasts and investigated the association with fibrosis. " 06/01/2015 - "Indeed, they overexpressed a cleaved uPAR form, exposing the uPAR88-92 region, and vitronectin, both involved in fibrosis and in the fibroblast-to-myofibroblast transition. " 12/01/2001 - "Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis." 12/01/1994 - "These findings suggested that vitronectin is deposited in injured tissue through the process of repair and fibrosis and plays an important role as an adhesive protein. " 04/01/1992 - "Plasma vitronectin decreased with increasing severity of cirrhosis according to Child's criteria. "
2.	Membranous Glomerulonephritis (Membranous Nephropathy) 01/01/1994 - "In membranous nephropathy, vitronectin was localized in subepithelial deposits and in epithelial cell foot processes and was intensely positive in the foot processes adjacent to subepithelial deposits. " 11/01/1996 - "In this study, the localization of plasminogen activator inhibitor-1 (PAI-1) and its association with glomerular subepithelial deposits of vitronectin (VN) in membranous nephropathy (MN) was evaluated. " 01/01/1994 - "Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy." 01/01/1994 - "In contrast, the deposition of vitronectin, C5b-9, alpha v beta 3, and alpha v was always less intense in minimal-change nephrotic syndrome than in membranous nephropathy. " 01/01/1994 - "Thus, membranous nephropathy featured increased localization of vitronectin, C5b-9, and vitronectin receptors both within and around the subepithelial deposits, suggesting that the mechanism of immune complex disposal via the vitronectin receptor and the vitronectin-C5b-9 complex, associated with complement activation due to subepithelial immune complex formation, may also be active."
3.	Hepatocellular Carcinoma (Hepatoma) 05/01/2014 - "This study sought to understand the effects of vitronectin (VTN) on the growth of SMMC-7721 hepatoma cells. " 01/01/2015 - "To explore if inhibition of vitronectin can be used for the treatment of hepatocellular carcinoma. " 01/01/2015 - "Vitronectin silencing inhibits hepatocellular carcinoma in vitro and in vivo." 12/01/2011 - "The area under the receiver operating characteristic curve generated through analyses of nonglycosylated tryptic peptide from vitronectin precursor protein was 0.978, the highest observed in a group of patients with hepatocellular carcinoma. " 08/01/2002 - "Hepatocytes are the main source of vitronectin, and the capacity to synthesize and secrete vitronectin is usually retained in hepatocellular carcinoma. "
4.	Glomerulonephritis 10/01/2011 - "Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis." 01/01/1993 - "The localization of C3d, a fragment produced by C3 activation and S-protein (vitronectin), a regulatory factor of C5b-9, was studied immunohistochemically in normal human kidney and renal biopsies from patients with several types of glomerulonephritis. " 03/01/2001 - "In 40 patients who underwent renal biopsy, the localizations of vitronectin and clusterin, both of which are regulatory proteins for TCC, were examined by immunofluorescence microscopy in conjunction with that of TCC for the study of the mechanism of local defense in glomerulonephritis. " 10/01/2011 - "Here, we evaluated the role of vitronectin (VTN; also known as complement S protein), the principal cofactor of the plasminogen activator inhibitor-1 (PAI-1), in a mouse model of acute glomerulonephritis. " 01/01/2008 - "The multifunctional protein vitronectin is present within the deposits associated with Alzheimer disease (AD), age-related macular degeneration (AMD), atherosclerosis, systemic amyloidoses, and glomerulonephritis. "
5.	Glioblastoma (Glioblastoma Multiforme) 12/01/1991 - "In a cell attachment assay, cultured glioblastoma cells attached to the parenchyma of glioblastoma tumor cryostat sections at the sites of vitronectin expression, but failed to attach to normal brain. " 10/10/2003 - "Glioblastoma cells utilize integrins alpha v beta 3 and alpha v beta 5 to mediate vitronectin attachment. " 12/01/1991 - "Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. " 12/01/1991 - "An examination of adult cerebral glioblastoma biopsy material for the expression of adhesive proteins that might potentiate adhesion and invasion demonstrated tumor cell-associated vitronectin (5/5). " 03/01/1988 - "The penetration of two human melanoma cell lines and a glioblastoma cell line through the human amniotic basement membrane and its underlying stroma was inhibited by all of the RGD-containing peptides except for the one that inhibits only the vitronectin attachment. "

Related Drugs and Biologics

1.	Fibronectins (Fibronectin)
2.	Collagen
3.	Plasminogen Activator Inhibitor 1
4.	Clusterin
5.	matrigel
6.	contortrostatin
7.	Snake Venoms (Snake Venom)
8.	Laminin (Merosin)
9.	Plasminogen Activators (Plasminogen Activator)
10.	Integrins

Related Therapies and Procedures

1.	Ligation
2.	Traction
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Intravitreal Injections